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Abstract
Background
Systematic collection of mortality/morbidity data over time is crucial for monitoring trends in 
population health, developing health policies, assessing the impact of health programs. In 
Poland, a comprehensive analysis describing trends in disease burden for major conditions 
has never been published. The Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) provides data on the burden of over 300 diseases in 195 countries since 1990. We 
used the GBD database to undertake an assessment of disease burden in Poland, evaluate 
changes in population health between 1990-2017, and compare Poland with other Central 
European (CE) countries.
Methods
The results of GBD 2017 for 1990 and 2017 for Poland and CE were used to assess rates 
and trends in years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted 
life years (DALYs). Data came from cause-of-death registration systems, population health 
surveys, disease registries, hospitalization databases, and the scientific literature. Analytical 
approaches have been used to adjust for missing data, errors in cause-of-death certification, 
and differences in data collection methodology. Main estimation strategies were ensemble 
modelling for mortality and Bayesian meta-regression for disability.
Results
Between 1990-2017, age-standardized YLL rates for all causes declined in Poland by 
46.0% (95% UI: 43.7-48.2), YLD rates declined by 4.0% (4.2-4.9), DALY rates by 31.7% 
(29.2-34.4). For both YLLs and YLDs, greater relative declines were observed for females. 
There was a large decrease in communicable, maternal, neonatal, and nutritional disease 
DALYs (48.2%; 46.3-50.4). DALYs due to non-communicable diseases (NCDs) decreased 
slightly (2.0%; 0.1-4.6). In 2017, Poland performed better than CE as a whole (ranked fourth 
for YLLs, sixth for YLDs, and fifth for DALYs) and achieved greater reductions in YLLs and 
DALYs than most CE countries. In 2017 and 1990, the leading cause of YLLs and DALYs in 
Poland and CE was ischaemic heart disease (IHD), and the leading cause of YLDs was low 
back pain. In 2017, the top 20 causes of YLLs and YLDs in Poland and CE were the same, 
although in different order. In Poland, age-standardized DALYs from neonatal causes, other 
cardiovascular and circulatory diseases, and road injuries declined substantially between 
1990-2017, while alcohol use disorders and chronic liver diseases increased. The highest
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observed-to-expected ratios were seen for alcohol use disorders for YLLs, neonatal sepsis 
for YLDs, and falls for DALYs (3.21, 2.65, and 2.03, respectively).
Conclusions
There was relatively little geographical variation in premature death and disability in CE in 
2017, although some between-country differences existed. Health in Poland has been 
improving since 1990; in 2017 Poland outperformed CE as a whole for YLLs, YLDs, and 
DALYs. While the health gap between Poland and Western Europe has diminished, it 
remains substantial. The shift to NCDs and chronic disability, together with marked 
between-gender health inequalities, poses a challenge for the Polish health-care system. 
IHD is still the leading cause of disease burden in Poland, but DALYs from IHD are declining. 
To further reduce disease burden, an integrated response focused on NCDs and population 
groups with disproportionally high burden is needed.
Introduction
Central Europe (CE) is a geographical region composed mostly of ex-communist countries and 
including Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, North 
Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia, and Slovenia. Since the 1990s, 
despite many earlier similarities in economic development and the organization of health care 
systems, this group of countries have been facing numerous health challenges as a result of the 
shift from previous centrally planned economies to market economies, the formation of new 
countries within the same territories, local conflicts, aging, as well as the adoption of some 
unhealthy elements of Western lifestyle [1]. Since 2004, the majority of CE countries have 
become members of the European Union, with the exception of Albania, North Macedonia, 
Montenegro, and Serbia (candidate countries), and Bosnia and Herzegovina (potential candi­
date). Although the region has historically seen overall improvements in life expectancy and 
other health indicators, there are still high disparities in their gross domestic product, socio­
demographic profiles, public health expenditures, health care coverage, and Human Develop­
ment Index (HDI) [2]. The HDI, which is a summary measure (between 0 and 1) for assessing 
progress in three basic dimensions of human development, i.e., a long and healthy life, access to 
knowledge, and a decent standard of living, varied markedly in 2018 across CE countries, rang­
ing from 0.768 to 0.896, while its mean value in Western Europe reached 0.920 [2].
In Poland, the biggest country in this region with a population of over 38 million, mortality 
due to cardiovascular disease, cancer, and injuries-the three leading causes of premature 
death-are gradually in decline, while life expectancy at birth is increasing [3, 4]. However, 
despite a high HDI (0.865 in 2017), total health expenditure in Poland, expressed as a percent­
age of gross domestic product (GDP), is one of the lowest in CE (6.5% in 2016) and much 
lower than in the European Union as a whole (8.4%) [5]. As the Polish population grows older, 
similar to other European populations [3, 4, 6], the number of years Poles can expect to live 
with disability and impaired quality of life from chronic conditions has increased [6, 7]. This 
suggests that declines in mortality have not been matched by similar declines in morbidity, 
resulting in people living longer with diseases. Indeed, a recent national report in Poland [7] 
showed an increasing prevalence of lower back pain, high blood pressure, neck pain, and oste­
oarthritis, suggesting that non-fatal outcomes of diseases along with injuries are becoming a 
larger component of the total burden of disease.
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Previous publications on the health status of Poles [3, 6, 8], based on routinely collected 
mortality and morbidity statistics and national surveys, are limited in scope and timeframe, 
and do not allow for a comprehensive comparison with other countries. In this study, we car­
ried out a systematic analysis of data from the Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) Study [9- 12], which provides the most comprehensive picture of health loss 
across countries to date. The purpose of the study was to present recent estimates of disease 
burden for a range of non-communicable and communicable diseases and injures, track 
trends and benchmark progress in disease burden reduction between 1990 and 2017, and com­
pare observed measures of disease burden to those expected on the basis the Socio-demo­
graphic Index (SDI), a summary measure of a geography’s socio-demographic development 
[ 13]. By considering the varying levels of development across the CE countries, the analyses 
reported here make it possible to evaluate each country’s performance relative to its peers. 
Hence, this report extends the results of previous research by using an improved methodologi­
cal approach to better understand the burden of disease at a regional level and provides data 
that are relevant to policy-makers.
Methods
The GBD is a large-scale scientific collaboration whose goal is to generate valid, comparable, 
and up- to-date information on mortality, morbidity, and risk factors for all countries over 
time [14]. The results are regularly updated by new data to improve the accuracy of past esti­
mates. The GBD database provides access to a complete set of age, national and subnational, 
and gender-specific estimates of burden across a wide range of causes. In the 2017 iteration of 
the GBD (GBD 2017), disease burden was estimated for 359 diseases (282 causes of death) 
from 1990 until 2017 for 195 countries [9- 12, 15]. Disease burden in GBD is measured with 
several population health indicators, including standard measures of disease frequency, such 
as death rates, disease incidence and prevalence, and life expectancy, and more complex indi­
cators, such as years of life lost (YLLs), years lived with disability (YLDs), and disability- 
adjusted life years (DALYs). YLLs are a measure of premature mortality. They are defined as 
the number of deaths from a disease multiplied by standard expected years of life at the time of 
death [9]. Standard expected years of life are obtained for each age from the country (popula­
tion > 5  million) with the highest life expectancy for that age, male or female [9]. YLDs are a 
measure of years of life lived with disability, defined as the number of people with a given dis­
ease (prevalence) multiplied by the corresponding disability weight, with different weights 
used for different disease stages or sequelae [11]. Finally, DALYs are defined as a sum of YLLs 
and YLDs and are considered an overall measure of population health that combines mortality 
and morbidity [12].
For the current study, we extracted GBD data for the period 1990 to 2017 for Poland, other 
CE countries, and the CE, Eastern Europe (Belarus, Estonia, Latvia, Lithuania, Moldova, Rus­
sian Federation, Ukraine), and Western Europe (Andorra, Austria, Belgium, Cyprus, Den­
mark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, 
Netherlands, Norway, Portugal, Switzerland, Spain, Sweden, United Kingdom) regions. Data 
on levels and trends in health had been provided by various data systems, including health sur­
veys [16], national registration of causes of death [17], infectious disease surveillance [18, 19], 
cancer registries [20], hospitalization data [21], and demographic censuses [16]. Additional 
data were obtained from the scientific literature, other published reports, and other sources 
[9- 12, 15]. The data were systematically collected, reviewed, and adjusted for missing data, 
errors in cause of death certification, and differences in disease definitions and data collection 
methodology across different data sources and locations, to produce valid, reproducible, and
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comparable estimates of disease burden. Death rates by age, gender, year, and location for 
most diseases were estimated using a statistical procedure developed for the GBD, the Cause of 
Death Ensemble model (CODEm) [10]. In ensemble modeling, the best prediction model for 
death rates is found as a weighted combination of a range of different models. These models 
are developed by systematically testing a large number of functional forms and combinations 
of covariates. The best performing models are selected based on out-of-sample predictive abil­
ity. Non-fatal outcomes were modeled with DisMod-MR 2.1, a Bayesian meta-regression tool 
developed specifically for the GBD. DisMod-MR 2.1 uses a compartmental model that com­
bines information from different sources and generates estimates of epidemiological parame­
ters adjusted for gaps and inconsistencies in the data. The parameters are estimated using 
Markov Chain Monte Carlo and Bayesian statistical methods [11, 22]. Details of data sources, 
bias-reduction methods, and statistical analyses are described in GBD capstone papers [9- 12, 
15] and other publications [22, 23].
In this study, we describe disease burden in terms of YLLs, YLDs, and DALYs. To assess 
the impact of aging on disease burden, we present both all-age (non-standardized) rates and 
age-standardized rates based on the GBD standard world population. We display the trends 
over time, describe the rates according to age and gender, and provide comparative data for 
CE as a whole as well as Western Europe (WE) and Eastern Europe (EE). In the GBD, diseases 
are grouped into hierarchically organized categories according to a 4-level classification sys­
tem. Level 1 has only three broad categories (non-communicable diseases, communicable, 
maternal, neonatal, and nutritional diseases, and injuries). There are 22 disease groups at Level 
2 (e.g., cardiovascular diseases), 169 conditions at Level 3 (e.g., stroke) and 293 at Level 4 (e.g., 
intracerebral hemorrhage) [9- 10]. With a few exceptions, we show disease-specific rates for 
Level 3 of the GBD hierarchy. Since conventional confidence intervals are not available for 
GBD estimates, 95% uncertainty intervals (UI) were generated by taking 1,000 draws from the 
posterior distribution of each estimate, with upper and lower bounds determined by the 25th 
and 975th values of the draws [9, 23].
The GBD Study groups countries according to their SDI. The SDI is defined as a combina­
tion (geometric mean) of lag distributed income per capita, average years of education for per­
sons 15 years of age or older, and fertility rate for women less than 25 years of age [11]. For 
each country and disease burden indicator, the expected value for a given year is calculated 
based on that country’s SDI and a model of the relationship between SDI and disease burden. 
We used the observed-to-expected ratios (OER) to assess how Poland is performing compared 
to its peers, i.e., other countries at a similar level of development.
The study utilized existing data and, therefore, does not require ethical approval. The GBD 
study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting 
(GATHER) recommendations [24].
Results
Years of life lost (YLLs)
Overview. Estimates of age-standardized YLL rates and ranking for all CE countries for 
the years 1990 and 2017 are shown in Table 1, and percentage changes for Poland, CE, EE, and 
WE are shown in Fig 1. Corresponding estimates of all-age YLLs are given in the S1 Table. 
Between 1990 and 2017, the age-standardized YLL rate in Poland decreased by 46.0%, from 
22,254 (95% UI: 22,166-22,346) to 12,007 (11,475-12,585) per 100,000. The rate decreased by 
45.1% in males and 48.3% in females (Fig 1). For comparison, the YLL rate in CE as a whole 
decreased by 43.4%, from 22,814 (22,752-22,879) to 12,910 (12,665-13,151), 42.4% in males 
and 45.3% in females. Of all CE countries, only Slovenia (52.9% in both males and females),
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Table 1. Age-standardized YLL, YLD, and DALY rates (95% UI) and country ranks (from best to worst) for Poland and other Central European countries, for both  
sexes combined, males, and females, in 1990 and 2017.
Country Age-standardized YLL rate  
per 100,000
Age-standardized YLD rate 
per 100,000
Age-standardized DALY rate 
per 100,000
1990 2017 1990 2017 1990 2017
Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank
Total
Central Europe 22,814 12,910 11,593 11,099 34,407 24,009
22,752-22,879 12,665-13,151 8,678-14,879 8,304-14,269 31,476-37,687 21,159-27,224
Albania 20,416 5 12,358 5 11,081 3 10,656 1 31,497 5 23,014 4
19,655-21,197 10,677-14,253 8,270-14,301 7,965-13,666 28,522-34,764 19,681-26,573
Bosnia 17,971 3 12,934 7 11,489 10 11,368 13 29,460 3 24,302 10
17,750-18,198 12,300-13,566 8,600-14,739 8,547-14,526 26,592-32,720 21,374-27,583
Bulgaria 21,413 7 15,799 13 11,150 5 10,743 2 32,562 6 26,542 12
21,240-21,601 14,998-16,607 8,268-14,357 8,015-13,881 29,717-35,723 23,670-29,676
Croatia 19,455 4 10,763 3 11,065 2 10,836 3 30,519 4 21,599 3
19,252-19,669 10,239-11,310 8,270-14,187 8,129-13,928 27,782-33,689 18,978-24,735
Czech Republic 21,232 6 10,093 2 11,465 7 11,289 11 32,697 7 21,382 2
21,075-21,391 9,609-10,616 8,543-14,829 8,457-14,631 29,851-35,985 18,556-24,811
Hungary 25,258 10 13,008 8 12,014 12 11,244 9 37,272 12 24,252 9
25,079-25,434 12,431-13,645 9,059-15,415 8,481-14,435 34,318-40,661 21,338-27,319
N. Macedonia 22,171 8 13,081 10 11,147 4 10,909 4 33,319 8 23,990 8
21,773-22,559 12,475-13,712 8,344-14,326 8,178-14,048 30,522-36,528 21,211-27,176
Montenegro 17,255 1 13,042 9 10,895 1 10,934 5 28,150 1 23,976 7
16,762-17,768 12,176-13,971 8,172-14,095 8,166-14,011 25,356-31,326 21,174-27,265
Poland 22,254 9 12,007 4 11,487 9 11,033 6 33,741.12 9 23,040 5
22,166-22,346 11,475-12,585 8,581-14,864 8,222-14,129 30,817-37,080 20,212-26,249
Romania 25,274 13 15,553 12 12,090 13 11,255 10 37,363 13 26,808 13
25,141-25,421 14,865-16,229 9,066-15,492 8,489-14,525 34,279-40,771 23,876-30,259
Serbia 23,746 12 14,382 11 11,330 6 11,086 7 35,076 11 25,468 11
23,514-23,967 13,733-15,007 8,495-14,595 8,319-14,247 32,212-38,318 22,684-28,807
Slovakia 22,272 11 12,376 6 11,470 8 11,091 8 33,741.48 10 23,466 6
22,077-22,479 11,765-13,031 8,578-14,793 8,314-14,282 30,840-37,072 20,562-26,795
Slovenia 17,472 2 8,413 1 11,560 11 11,290 12 29,032 2 19,703 1
17,232-17,702 7,909-8,954 8,623-14,829 8,443-14,528 26,074-32,329 16,907-23,034
Males
Central Europe 30,187 17,385 11,678 11,278 41,864 28,662
30,098-30,272 16,933-17,814 8,767-14,985 8,489-14,446 38,905-45,161 25,786-31,912
Albania 25,499 4 16,473 6 11,077 2 10,730 1 36,576 4 27,204 4
24,643-26,395 13,501-19,697 8,251-14,222 8,009-13,783 33,654-39,816 22,963-31,677
Bosnia 22,966 2 16,217 4 11,415 7 11,620 13 34,381 2 27,837 6
22,659-23,267 15,216-17,296 8,562-14,565 8,755-14,738 31,566-37,611 24,816-31,218
Bulgaria 28,082 7 21,177 13 11,289 6 10,826 2 39,371 7 32,004 12
27,841-28,342 19,842-22,524 8,412-14,496 8,105-13,974 36,427-42,567 29,054-35,361
Croatia 26,440 6 14,587 3 11,225 4 11,073 5 37,664 6 25,660 3
26,167-26,730 13,649-15,539 8,398-14,371 8,296-14,185 34,822-40,903 22,906-28,866
Czech Republic 29,148 8 13,297 2 11,468 8 11,497 11 40,616 8 24,794 2
28,938-29,371 12,422-14,211 8,601-14,810 8,640-14,811 37,752-43,974 21,801-28,233
(C ontinued )
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Table 1. (Continued)
Country Age-standardized YLL rate  
per 100,000
Age-standardized YLD rate 
per 100,000
Age-standardized DALY rate 
per 100,000
1990 2017 1990 2017 1990 2017
Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank
Hungary 34,231 13 17,763 11 12,013 12 11,335 9 46,244 13 29,098 11
33,984-34,481 16,726-18,952 9,075-15,403 8,585-14,551 43,284-49,640 26,111-32,381
N. Macedonia 25,974 5 17,103 9 11,211 3 11,067 4 37,185 5 28,169 8
25,493-26,454 16,021-18,193 8,354-14,380 8,280-11,201 34,407-40,437 25,174-31,583
Montenegro 22,155 1 16,334 5 10,961 1 11,005 3 33,116 1 27,339 5
21,514-22,816 14,783-18,030 8,217-14,127 8,209-14,045 30,239-36,267 24,205-30,925
Poland 30,723 9 16,859 8 11,629 9 11,329 8 42,352 10 28,189 9
30,604-30,849 15,886-17,913 8,700-14,952 8,502-14,568 39,440-45,708 25,080-31,592
Romania 31,464 12 20,923 12 12,181 13 11,299 7 43,645 12 32,222 13
31,275-31,665 19,747-22,222 9,163-15,614 8,468-14,597 40,598-47,082 29,074-35,637
Serbia 30,869 11 17,172 10 11,283 5 11,114 6 42,153 9 28,286 10
30,570-31,183 16,116-18,198 8,457-14,443 8,342-14,243 39,334-45,345 25,373-31,735
Slovakia 30,729 10 16,593 7 11,755 10 11,375 10 42,484 11 27,968 7
30,448-31,028 15,590-17,597 8,819-15,133 8,527-14,666 39,443-45,914 24,961-31,496
Slovenia 24,385 3 11,497 1 11,803 11 11,522 12 36,188 3 23,019 1
24,047-24,760 10,635-12,328 8,794-15,144 8,617-14,787 33,250-39,646 20,091-26,322
Females
Central Europe 16,427 8,986 11,528 10,952 27,954 19,938
16,361-16,499 8,746-9,229 8,582-14,898 8,177-14,163 25,020-31,298 17,134-23,081
Albania 15,944 9 8,580 5 11,103 6 10,597 1 27,047 9 19,177 5
15,256-16,653 6,939-10,395 8,273-14,469 7,929-13,687 24,082-30,284 15,963-22,625
Bosnia 13,673 3 9,993 9 11,589 12 11,143 11 25,262 4 21,136 10
13,445-13,912 9,306-10,738 8,699-14,844 8,354-14,328 22,352-28,585 18,265-24,307
Bulgaria 15,343 8 11,057 12 11,031 4 10,689 3 26,373 7 21,746 11
15,160-15,544 10,324-11,847 8,210-14,273 7,992-13,820 23,560-29,565 18,855-24,784
Croatia 13,748 4 7,458 3 10,947 2 10,626 2 24,695 3 18,084 2
13,508-13,979 6,926-8,027 8,191-14,039 7,980-13,665 21,915-27,839 15,398-21,153
Czech Republic 14,783 5 7,255 2 11,472 11 11,115 10 26,254 5 18,369 3
14,622-14,955 6,765-7,797 8,580-14,845 8,283-14,431 23,422-29,535 15,503-21,699
Hungary 17,714 11 9,156 7 12,022 3 11,193 12 29,736 12 20,349 7
17,528-17,894 8,549-9,844 8,981-15,513 8,390-14,452 26,741-33,197 17,472-23,466
N. Macedonia 18,623 12 9,687 8 11,090 5 10,771.53 4 29,713 11 20,459 8
18,180-19,056 9,092-10,293 8,266-14,279 8,048-13,921 26,850-32,886 17,629-23,663
Montenegro 12,961 2 10,080 10 10,866 1 10,878 7 23,816 2 20,958 9
12,492-13,463 9,297-10,940 8,110-14,103 8,165-14,079 21,032-27,006 18,005-24,110
Poland 15,102 7 7,810 4 11,361 8 10,772.41 5 26,464 8 18,582 4
15,005-15,210 7,315-8,340 8,432-14,753 8,051-13,865 23,567-29,802 15,853-21,677
Romania 19,541 13 10,758 11 12,023 13 11,251 13 31,564 13 22,009 12
19,366-19,718 10,100-11,408 8,994-15,538 8,443-14,586 28,493-35,044 19,169-25,402
Serbia 17,584 10 11,612 13 11,400 10 11,067 8 28,983 10 22,680 13
17,363-17,802 10,815-12,365 8,569-14,703 8,344-14,245 26,160-32,301 19,928-25,785
Slovakia 15,066 6 8,811 6 11,234 7 10,858 6 26,300 6 19,669 6
14,841-15,280 8,180-9,478 8,386-14,568 8,128-14,050 23,439-29,659 17,003-22,833
(C ontinued)
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Table 1. (Continued)
Country Age-standardized YLL rate 
per 100,000
Age-standardized YLD rate 
per 100,000
Age-standardized DALY rate 
per 100,000
1990 2017 1990 2017 1990 2017
Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank Rate 
95% UI
Rank
Slovenia 11,971 1 5,643 1 11,364 9 11,073 9 23,336 1 16,716 1
11,686-12,264 5,144-6,179 8,491-14,658 8,247-14,277 20,436-26,591 13,905-19,992
In 2017, age-standardized YLL rates in WE were much lower than in Poland, at 7,901 per 100,000 overall (95% UI: 7,728-8,082), 10,014 (9,717-10,336) in males and 
5,985 (5,792-6,190) in females (Fig 1). In EE, on the other hand, the rates were higher, at 20,995 (20,752-21,243) overall, 30,859 (30,391-31,306) in males and 13,076 
(12,870-13,290) in females. YLL rates in WE declined by 44.1% (46.7% in males and 41.5% in females) between 1990 and 2017. In the same period, the rates in EE 
declined by only 16.4% (14.1% and 22.1%, respectively).
https://doi.ora/10.1371/journal.pone.0226766.t001
the Czech Republic (54.4% and 50.9%, respectively), and Hungary (48.1% and 48.3%, respec­
tively) experienced greater declines in age-standardized YLL rates in the above mentioned 
period. Other CE countries also experienced a reduction in YLL rates, although not as large. 
The smallest decrease was observed in Montenegro (24.4%). In 2017, Poland performed better 
than CE as a whole and achieved a greater improvement in rank since 1990 (from ninth to 
fourth) than any other CE country but Slovakia (from 11th to sixth).
Rate(2017) % change
50 ,000
a_i>-
50 ,000
<a
50 ,000 40 ,000  30 ,000  20 ,000  10,000
per 100,000
20 30
% change
Fig 1. Age-standardized rates in 2017 (left) and relative (%) change from 1990 to 2017 (right) for YLLs, YLDs, and 
DALYs for males, females, and both sexes combined for Poland, Eastern Europe, Central Europe, and Western Europe.
https://doi.ora/10.1371/journal.pone.0226766.a001
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Table 2. All-age rates, percentage contribution, and relative (%) change for Level 1 causes o f YLLs, YLDs, and DALYs for Poland and Central Europe, both sexes 
combined, in 1990 and 2017.
Cause All-age YLL rate All-age YLD rate All-age DALY rate
1990 2017 1990 2017 1990 2017
Rate per Contribution % Rate per Change Rate per Contribution % Rate per Change Rate per Contribution % Rate per Change
100,000 (95% UI) 100,000 % 100,000 (95% UI) 100,000 % 100,000 (95% UI) 100,000 %
Poland
CMMN 1,996.5 4.2
3.9-4.4
767.2 -61.6 1,048.4 5.7
4.5-7.1
810.2 -22.7 3,044.8 4.8
4.3-5.4
1,577.4 -48.2
NCDs 18,348.2 85.7
85.2-86.1
15,825.5 -13.8 9,179.5 78.2
75.9-80.2
11,154.3 21.5 27,527.7 82.4
81.3-83.5
26,980.0 -2.0
Injuries 3,078.4 10.2
9.9-10.5
1,881.1 -38.9 2,010.2 16.1
14.4-18.1
2,303.1 14.6 5,088.6 12.7
11.8-13.9
4,184.2 -17.8
Central Europe
CMMN 2,406.5 4.1
4.0-4.2
834.9 -65.31 1,055.4 5.8
4.9-7.0
839.3 -20.5 3,461.8 4.8
4.4-5.2
1,674.1 -51.6
NCDs 19,068.0 87.6
87.5-87.8
17,821.8 -6.5 9,508.9 78.5
76.3-80.6
11,364.0 19.5 28,576.8 83.9
82.7-84.9
29,185.8 2.1
Injuries 3,061.1 8.3
8.1-8.4
1,677.8 -45.2 2,047.2 15.7
14.0-17.6
2,270.7 10.9 5,108.3 11.3
10.4-12.4
3,948.4 -22.7
https://doi.ora/10.1371/journal.pone.0226766.t002
Main causes o f YLLs. Looking at Level 1 causes, communicable, maternal, neonatal, and 
nutritional diseases (CMNN) contributed 4.2% (95% UI: 3.9-4.4) to total all-age YLLs in 
Poland in 2017, non-communicable diseases (NCD) contributed 85.7% (85.2-86.1), and inju­
ries 10.2% (9.9-10.5) (Table 2). Significant progress has been made for CMNN, which declined 
by 61.6% between 1990 and 2017, from 1,996.5 to 767.2 per 100,000, as well as for injuries 
(38.9% decline, from 3,078.4 to 1,881.1), and NCDs (13.8% decline, from 18,348.2 to 15,825.5). 
In CE, CMNN causes contributed 4.1% (4.0-4.2) to total YLLs in 2017, NCDs contributed 
87.6% (87.5-87.8), and injuries 8.3% (8.1-8.4). All-age YLL rates for CMNN causes fell by 
65.3%, from 2,406.5 per 100,000 in 1990 to 834.9 in 2017, whereas those from injuries fell by 
45.2%, from 3,061.1 to 1,677.8, and those from NCDs by 6.5%, from 19,068.0 to 17,821.8. YLL 
rates for 22 major groups of conditions (Level 2 of the GBD hierarchy) are provided in the S2 
Table.
Table 3 lists the top 25 Level 3 causes of age-standardized YLLs for Poland in 2017, com­
pared to 1990, for both sexes combined, as well as percentage changes in counts, all-age rates, 
and age-standardized rates. In 2017, the top five causes were ischemic heart disease (IHD), 
lung cancer, stroke, self-harm, and colorectal cancer. Age-standardized rates decreased sub­
stantially between 1990 and 2017 for IHD (63.3%) and stroke (51.2%), somewhat less for lung 
cancer (15.4%) and only slightly for colorectal cancer (6.7%); however, rates remained virtually 
unchanged for self-harm. The remaining top 10 causes of YLLs were road injuries, chronic 
liver diseases, neonatal disorders, lower respiratory infections, and Alzheimer’s disease. Of 
those, age-standardized rates increased (33.9%) for chronic liver diseases.
When looking at changes in ranks from 1990 to 2017 in Poland (Table 3), IHD remained 
the top cause of YLLs throughout this period. The largest increases among the top 10 causes 
were noted for chronic liver diseases (8 places), followed by colorectal cancer (4), lung cancer 
(3), self-harm (3), and Alzheimer’s disease (2), whereas decreases were seen for neonatal disor­
ders (5), road injuries (2), stroke (1), and lower respiratory infections (1). Among the remain­
ing top 25 causes, prostate and kidney cancer showed the greatest increase in ranks (16 and 14 
places, respectively). Increases in ranks were also observed for alcohol use disorders (8 places); 
several cancers, including ovarian (10), pancreatic (6), brain (5), leukemia (5), breast (3), and
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Table 3. Top 25 Level 3 causes ofY LLs, YLDs, and DALYs in Poland in 2017 for both sexes combined, males, and females, and changes in ranks, counts, all-age 
rates, and age-standardized rates between 1990 and 2017.
T O T A L
# YLLs change 
in rank
%
change 
in counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
YLD s change 
in rank
%
change
in
counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
D A LYs change 
in rank
%
change
in
counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
1. Ischem ic heart 
disease
0 -42.5 -41.5 -63.3 Low back pain 0 25.6 27.8 1.3 Ischem ic heart 
disease
0 -41.0 -40.0 -62.2
2. Lung cancer +3 24.7 26.9 -15.4 Falls 0 16.6 18.6 -7.6 Low back pain +4 25.6 27.8 1.3
3. Stroke -1 -25.1 -23.8 -51.2 Headache
disorders
0 5.7 7.6 0.02 Falls +  1 10.8 12.8 -13.0
4. Self-harm +3 6.9 8.7 0.3 N eonatal
disorders
0 -4.0 -2.3 6.5 Stroke -1 -17.0 -15.6 -45.8
5. Colorectal cancer +4 38.3 40.7 -6.7 Diabetes +2 62.9 65.8 21.2 Neonatal disorders -3 -59.2 -58.5 -56.9
6. Road injuries -2 -62.2 -61.5 -62.2 Age-related 
hearing loss
-1 35.2 37.5 -2.9 Lung cancer +2 24.8 27.0 -15.3
7. Chronic liver 
diseases
+8 69.6 72.6 33.9 Depressive
disorders
+  1 13.7 15.7 -0.9 Headache
disorders
+3 5.7 7.6 0.02
8. N eonatal
disorders
-5 -85.8 -84.8 -77.3 Anxiety
disorders
+3 4.4 6.2 -0.01 Road injuries -3 -48.0 -47.0 -52.5
9. Lower respiratory 
infect.
-1 -9.9 -8.3 -42.4 N eck pain +3 25.9 28.1 0.05 Diabetes +2 27.9 32.0 -5.0
10. Alzheimer’s
disease
+2 65.1 67.9 -13.1 COPD -4 10.2 12.1 -24.5 Self-harm +2 7.0 8.8 0.22
11. Alcohol use 
disorders
+9 51.5 54.1 27.9 Blindness and 
vision 
im pairm ent
-1 21.6 23.7 -10.1 COPD -2 -3.7 -2.0 -35.7
12. Congenital defects -6 -78.8 -78.4 -69.9 Oral disorders -3 11.4 13.3 -12.8 Alcohol use 
disorders
+5 39.0 41.4 20.2
13. Cardiom yopathy +  1 33.6 35.9 -11.8 U pper digestive 
diseases
+2 4.3 6.1 -6.0 Congenital defects -6 -61.8 -61.1 -58.2
14. COPD -4 -15.7 -14.3 -45.6 Stroke -1 31.3 33.6 -13.2 Chronic liver 
diseases
+9 72.0 75.0 36.2
15. Breast cancer +3 12.3 14.3 -19.4 Road injuries -1 2.3 4.1 -14.8 Colorectal cancer +  1 39.6 42.0 -5.8
16. Stom ach cancer -5 -30.5 -29.3 -51.5 Congenital
defects
0 -3.9 -2.3 -1.5 Alzheimer’s
disease
-2 67.8 70.7 -17.7
17. Pancreatic cancer +6 29.9 32.1 -10.6 Alcohol use 
disorders
-3 20.5 22.6 9.3 Age-related 
hearing loss
+  1 35.2 37.5 -2.9
18. Falls -1 -12.3 -10.7 34.6 M echanical
forces
0 14.4 16.4 -3.4 Depressive
disorders
+4 13.7 15.7 -0.9
19. Diabetes -3 -12.3 -10.7 -39.2 Asthm a -2 -9.7 -8.2 -11.4 Lower respiratory 
infections
-6 -9.9 -8.4 -42.1
20. Brain cancer +5 8.2 10.1 -12.7 Dermatitis +2 -11.4 -9.9 1.0 U pper digestive 
diseases
0 2.7 4.4 -12.7
21. Leukemia +5 -5.3 -3.7 -29.5 Gynecological
diseases
0 -3.5 -1.9 -5.9 Cardiom yopathy 0 36.1 38.5 -10.1
22. Other malignant 
neoplasm s
+2 -19.4 -18.0 -37.9 Other mental 
disorders
+2 14.6 16.6 0.5 Anxiety disorders +5 4.4 6.2 -0.01
23. Ovarian cancer +  10 26.7 28.9 -9.6 D rug use 
disorders
+4 11.8 13.8 11.0 N eck pain +6 25.9 28.1 0.05
24. Prostate cancer +  16 85.2 88.4 18.7 Bipolar disorder +  1 5.1 6.9 -0.04 Blindness and 
vision im pairm ent
+  1 21.6 23.7 -10.1
25. K idney cancer +  14 52.5 55.2 5.9 Schizophrenia +3 17.1 19.1 3.9 Oral disorders -1 11.4 13.3 -12.8
M A LE S
# YLLs change 
in rank
%
change 
in counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
Y LD s change 
in rank
%
change
in
counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
D A LYs change 
in rank
%
change
in
counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
1. Ischem ic heart 
disease
0 -44.3 -42.9 -63.4 Falls 0 16.5 19.4 -5.3 Ischem ic heart 
disease
0 -43.1 -41.6 -62.6
2. Lung cancer 0 5.3 8.0 -29.6 Low back pain 0 26.7 29.9 2.6 Falls +4 10.8 13.6 -10.8
3. Self-harm +3 11.7 14.5 3.9 N eonatal
disorders
+  1 -2.0 0.5 10.7 Lung cancer +2 5.3 8.0 -29.5
4. Stroke -1 -17.4 -15.3 -45.0 Headache
disorders
-1 5.2 7.9 0.1 Stroke -1 -10.5 -8.3 -40.3
5. Road injuries 0 -63.1 -62.2 -63.7 Diabetes +  1 74.8 79.2 28.6 Low back pain +3 26.6 29.8 2.5
6. Chronic liver 
diseases
+8 78.6 83.2 34.8 Age-related 
hearing loss
-1 32.1 35.4 -3.8 Self-harm +4 11.7 14.5 3.8
(Continued  )
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T ab le3 . (Continued)
7
Alcohol use 
disorders
+6 45.7 49.4 22.0 Depressive
disorders
+3 17.1 20.1 5.3 Neonatal disorders -5 -61.8 -60.8 -58.6
8. Colorectal cancer +4 59.7 63.7 6.2 Road injuries 0 -3.9 -1.4 -20.0 Road injuries -4 -52.7 -51.5 -56.2
9. Lower respiratory 
infections
0 -7.1 -4.7 -36.5 Blindness and 
vision 
im pairm ent
0 19.9 23.0 -10.1 Alcohol use 
disorders
+3 37.2 40.6 17.2
10. Cardiom yopathy +7 45.8 49.5 -1.8 COPD -3 8.5 11.3 -26.7 Diabetes +3 50.3 54.1 9.2
11. N eonatal
disorders
-7 -85.4 -85.1 -77.8 M echanical
forces
+1 15.6 18.5 -3.5 Chronic liver 
diseases
+7 81.4 86.0 37.4
12. COPD -4 -26.8 -24.9 -53.1 Alcohol use 
disorders
+3 21.4 24.5 8.6 COPD -3 -15.2 -13.0 -44.6
13. Congenital defects -6 -78.3 -77.7 -69.5 N eck pain +1 26.6 29.8 0.0 Colorectal cancer +4 61.2 65.3 7.1
14. Alzheimer’s
disease
+4 67.2 71.5 -12.1 Stroke -1 38.2 41.7 -7.2 Headache
disorders
+2 5.2 7.8 0.1
15. Falls +  1 -7.1 -4.8 -28.0 Oral disorders -4 13.8 16.7 -11.1 Congenital defects -8 -62.9 -62.0 -58.3
16. Stom ach cancer -6 -28.1 -26.2 -51.5 U pper digestive 
diseases
0 10.7 13.5 -1.2 Lower respiratory 
infections
-5 -7.1 -4.7 -36.2
17. Prostate cancer -6 85.2 89.9 14.3 Anxiety
disorders
0 2.3 4.9 0.3 Cardiom yopathy +3 47.4 51.1 -0.6
18. Diabetes +2 15.0 17.9 -19.0 Congenital
defects
0 -5.7 -3.3 -1.6 Age-related 
hearing loss
+5 32.0 35.4 -3.8
19. Pancreatic cancer +3 27.0 30.3 -13.8 D rug use 
disorders
+  1 12.4 15.2 11.6 Alzheimer’s
disease
0 69.4 73.7 -10.9
20. Brain cancer +9 10.3 13.1 -10.4 Asthm a -1 -15.8 -13.7 -14.7 U pper digestive 
diseases
+4 3.5 6.1 -14.3
21. Bladder cancer +  10 54.0 57.9 -0.3 Other mental 
disorders
0 14.1 17.0 0.0 M echanical forces 0 -10.9 -8.7 -25.1
22. Leukemia +3 -0.6 2.0 -24.9 Dermatitis +1 -11.9 -9.6 1.1 Depressive
disorders
+6 17.1 20.0 5.3
23. Drow ning -8 -62.0 -70.0 -63.9 Bipolar disorder +2 5.2 7.9 -0.1 Stom ach cancer -8 -27.9 -26.1 -51.4
24. K idney cancer +  15 62.0 66.1 12.4 Ischem ic heart 
disease
-2 17.2 20.2 -22.3 Prostate cancer +  10 94.1 99.0 19.3
25. Other malignant 
neoplasm s
+  1 -85.4 -20.4 -39.9 Conduct
disorder
+  1 -39.4 -38.0 0.2 Blindness and 
vision im pairm ent
+2 19.9 22.9 -10.1
FEM A LES
# YLLs change 
in rank
%
change 
in counts
%
change 
in  all­
age 
rates
% change in 
age-standar­
dized  rates
Y LD s change 
in rank
%
change
in
counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
D A LYs change 
in rank
%
change
in
counts
%
change 
in all­
age 
rates
% change in 
age-standar­
dized  rates
1. Ischem ic heart 
disease
0 -39.5 -38.9 -64.0 Low back pain 0 24.7 25.9 0.1 Low back pain +3 24.7 25.9 0.1
2. Stroke 0 -32.2 -31.5 -57.5 Headache
disorders
0 5.9 7.0 0.5 Ischem ic heart 
disease
-1 -37.4 -36.8 -62.4
3. Lung cancer +8 123.7 125.9 56.3 Falls 0 16.7 17.8 -9.8 Headache
disorders
+4 5.9 7.0 0.5
4. Breast cancer +  1 11.9 13.0 -18.6 N eonatal
disorders
0 -6.0 -5.0 2.5 Falls +2 10.8 11.8 -15.6
5. Alzheimer’s
disease
+4 64.0 65.6 -13.5 Age-related 
hearing loss
0 37.6 38.9 -2.3 Stroke -2 -22.7 -21.9 -50.8
6. Colorectal cancer +  1 17.1 18.2 -20.0 Anxiety
disorders
+  1 5.5 6.5 0.3 Neonatal disorders -4 -55.7 -55.3 -54.5
7. N eonatal
disorders
-4 -84.5 -84.4 -76.4 Diabetes +3 51.2 52.7 12.5 Diabetes +  1 11.5 12.6 -18.6
8. Congenital defects -4 -79.3 -79.1 -70.2 Depressive
disorders
0 11.2 12.3 -5.0 Lung cancer +  16 123.8 126.1 56.4
9. Ovarian cancer + 6 26.6 27.9 -8.7 N eck pain +2 25.4 26.6 0.4 Congenital defects -4 -60.4 -60.0 -57.9
10. Lower respiratory 
infect
-4 -14.5 -13.7 -49.9 COPD -4 11.3 12.4 -22.3 Breast cancer +  1 16.2 17.4 -15.4
11. Chronic liver 
disease
+  10 49.5 51.0 21.9 Oral disorders -2 9.7 10.8 -13.4 COPD -1 13.0 14.1 -22.9
12. Road injuries -5 -57.8 -57.4 -56.6 Gynecological
diseases
0 -3.5 -2.5 -5.0 Alzheimer’s
disease
0 67.0 68.6 -12.0
13. Cardiom ypathy 0 18.2 19.4 -28.4 Blindness and 
vision 
im pairm ent
0 22.9 24.2 -10.1 Age-related 
hearing loss
+2 37.6 38.9 -2.3
14. Cervical cancer -4 -33.8 -33.1 -49.9 U pper digest 
diseases
+  1 -0.9 0.0 -10.0 Anxiety disorders +2 5.5 6.5 0.3
(Continued  )
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15. Pancreatic cancer +8 33.3 34.6 -7.4 Stroke -1 26.6 27.9 -17.0 Road injuries -6 -31.9 -31.2 -40.0
16. Self-harm +2 -18.8 -18.0 -23.5 Congenital
defects
+2 -2.2 -1.2 -1.2 Depressive
disorders
+  1 11.2 12.3 -5.0
17. COPD +2 16.5 17.6 -24.1 Road injuries 0 11.8 12.9 -7.2 Colorectal cancer -3 18.0 19.2 -19.3
18. Brain cancer +6 5.5 6.6 -16.0 Asthm a +  1 -4.0 -3.1 N eck pain +4 25.4 26.6 0.4
19. Diabetes -7 -32.9 -32.2 -56.0 Dermatitis +  1 -11.0 -10.1 Oral disorders -1 9.7 10.8 -13.4
20. Other malignant 
neoplasm s
+2 -15.9 -15.0 -36.1 Bipolar disorder +2 5.0 6.0 U pper digest 
diseases
+  1 1.6 2.6 -12.6
21. Stom ach cancer -5 -35.7 -35.1 -53.5 Schizophrenia +3 15.9 17.0 3.6 Gynecological
diseases
+2 -4.5 -3.5 -5.8
22. Leukemia +3 -11.8 -11.0 -35.7 Other mental 
disorders
+3 15.3 16.5 0.4 Blindness and 
vision im pairm ent
+3 22.9 24.2 -10.1
23. Gallbladder
cancer
+5 -11.4 -10.5 -38.9 Alcohol use 
disorders
+5 18.2 19.3 9.7 Chronic liver 
diseases
+  11 51.8 53.3 24.3
24. Allcohol use 
disorders
+26 110.8 112.9 80.4 Osteoarthritis +6 59.7 61.3 11.2 Ovarian cancer +5 26.8 28.0 -8.4
25. Uterine cancer +7 36.4 37.8 -6.8 Epilepsy +2 4.4 5.4 2.9 Lower respiratory 
infect
-12 -14.5 -13.7 -49.6
Colors indicate changes in ranks: redz = increase, green = decrease, and blue = no change 
Color ranges were presented as follows
Decrease: <40  light green, 40-79 green, > 7 9  dark green; Increase: <40  light red, 40-79 red, >79  dark red. 
https://doi.ora/10.1371/iournal.pone.0226766.t003
other malignant neoplasms (2); and cardiomyopathy (1). Declines were seen for congenital 
defects (6 places) as well as stomach cancer (5), chronic obstructive pulmonary disease 
(COPD) (4), diabetes (3), and falls (1).
There were notable differences in YLL ranking and trends according to sex. Among males, 
the top five causes of YLLs were IHD, lung cancer, self-harm, stroke, and road injuries, 
whereas among females the order was IHD, stroke, lung cancer, breast cancer, and Alzheimer’s 
disease (Table 3). Road injuries were ranked 12th for females and self-harm was ranked 16th. 
Furthermore, age-standardized rates for lung cancer decreased in males (29.6%) but increased 
substantially in females (56.3%). In males, both age-standardized and all-age rates increased 
for prostate cancer and chronic liver diseases. For both genders, all-age YLL rates decreased 
for IHD and stroke, despite population aging.
The trends observed in Poland were largely consistent with CE patterns S1A Fig. IHD was 
the leading cause of age-standardized YLLs in CE as a whole, and stroke was the second lead­
ing cause. However, alcohol use disorders ranked 11th in Poland in 2017, but 20th in the region. 
Conversely, hypertensive heart disease ranked 15th in the region, whereas in Poland it 
decreased by 45% since 1990 and ranked 31st.
Deviations from expected levels based on SDI
Fig 2 illustrates OER ratios for age-standardized YLL rates in CE countries in 2017. Significant 
differences were observed between countries, with Albania having the lowest (0.65) and Bul­
garia the highest (1.10) ratio in the region. Of note, in 10 locations OERs were below 1.0; 
Poland’s OER was 0.96.
In 2017, of the 10 leading causes of YLLs in CE, YLL rates were lower than expected for 
neonatal preterm birth complications (0.70), self-harm by other means (0.76), COPD (0.91), 
and Alzheimer’s disease (0.94) (Fig 3A). OERs were less than 1 for IHD in six CE countries; 
the lowest OER was observed in Slovenia (0.49). On the other hand, YLLs were much higher 
than expected for alcoholic cardiomyopathy in Montenegro (7.39); hypertensive heart disease
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Fig 2. Observed-to-expected ratios for age-standardized YLL, YLD, and DALY rates for both sexes from  all causes in Central European countries in 2017. 
https://doi.ora/10.1371/iournal.pone.0226766.a002
in Bulgaria (5.60), Romania (3.79), and Hungary (3.62); intracerebral hemorrhage and diabetes 
in Montenegro (4.40 and 3.57, respectively); and alcohol use disorders in Poland (3.21).
Years lived with disability (YLDs)
Overview. Between 1990 and 2017, the age-standardized all-cause YLD rate in Poland 
decreased by 4.0%, from 11,487 (95% UI: 8,581-14,864) to 11,033 (8,222-14,129) per 100,000 
(Table 1, Fig 1). The rate declined by 2.6% in males and 5.2% in females. In CE as a whole, the 
rate decreased from 11,593 (8,678-14,879) to 11,099 (8,304-14,269) per 100,000 (4.3%) in the 
same period. Of all CE countries, only Romania and Hungary experienced greater reductions 
in YLD rates than Poland (6.9% and 6.4%, respectively). In 2017, the lowest rate in the region 
was observed in Albania (10,656; 7,965-13,666) and the highest in Bosnia and Hercegovina 
(11,368; 8,347-14,526). For comparison, overall age-standardized YLD rates in 2017 were 
10,635 per 100,000, (8,012-13,711) in WE and 11,415 (8,855-14,736) in EE. However, the 
rank-order of the three regions varied by sex (Fig 1). In males, YLD rates were lowest in WE 
(9,936; 7,486-12,852) followed by EE (11,095; 8,320-14,306) and CE (11,228; 8,489-14,446), 
whereas in females, the rates were lowest in CE (10,952; 8,177-14,163), followed by WE 
(11,351; 8,516-14,645) and EE (and 11,714; 8,777-15,079).
Main causes o f YLDs. In 2017, CMNN causes contributed 5.7% (95% UI: 4.5-7.1) to all­
age YLDs in Poland, NCDs contributed 78.2% (75.9-80.2), and injuries 16.1% (14.4-18.1) 
(Table 2). Of note, while a significant decline for CMNN-attributed YLDs was observed from 
1990 to 2017 (22.7%, from 1,048.4 to 810.2 per 100,000), it was accompanied by increases for 
NCDs (21.5%, from 9,179.5 to 11,154.3) and injuries (14.6%, from 2,010.2 to 2,303.1) in the 
same period. In CE, CMNN causes contributed 5.8% (4.9-7.0) to total YLDs, NCDs contrib­
uted 78.5% (76.3-80.6), and injuries 15.7% (14.0-17.6). All-age YLD rates for CMNN causes 
fell by 20.5%, from 1,055.4 per 100,000 in 1990 to 839.3 in 2017, whereas those from NCDs 
increased by 19.5%, from 9,508.9 to 11,364.0 and those from injuries by 15.7%, from 2,047.2 to 
2,270.7. YLD rates for Level 2 causes (22 groups of conditions) are provided in the S2 Table.
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Central Europe Albania Bosnia Bulgaria Croatia Czech Republic Hungary Macedonia Montenegro Poland Romania Serbia Slovakia Slovenia
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Fig 3. Leading Level 4 causes o f YLLs (a), YLDs (b), and DALYs (c) in Central European countries, with the ratio o f observed to expected (OER) age-standardized rates 
by location: (a) YLLs, (b) YLDs, (c) DALYs. Colors represent OER ranges: 0-0.54 = blue, 0.55-0.69 = green, 0.70-0.84 = light green, 0.85-0.99 = yellow green,
1.0 = white, 1.01-1.24 = dark yellow, 1.25-1.66 = orange, 1.67-2.91 = dark orange, 2.92+ = red.
https://doi.ora/10.1371/journal.pone.0226766.a003
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In 2017, the top 10 Level 3 causes of age-standardized YLDs in Poland were low back pain, 
falls, headache disorders, neonatal disorders, diabetes, age-related hearing loss, depressive dis­
orders, anxiety disorders, neck pain, and COPD (Table 3). Between 1990 and 2017, changes in 
the rank-order of the top five conditions were minimal. Among the top 25 causes of YLDs, 
declines in age-standardized rates were observed for 15; however, the declines did not exceed 
10%, except for COPD (24.5%), road injuries (14.8%), stroke (13.2%), oral disorders (12.8%), 
asthma (11.4%), and blindness and vision impairment (10.1%). Diabetes, drug use, and alcohol 
use disorders showed the largest increases in rates (21.2%, 11.0%, and 9.3%, respectively). The 
greatest differences between change in all-age and age-standardized rates (30% or greater) 
were noted for diabetes, osteoarthritis, and stroke, indicating that these diseases largely affect 
the elderly and, therefore, become more prominent causes of YLDs in an ageing population.
While the top four causes of YLDs were the same in males and females, ranking of the con­
ditions differed (Table 3). Other sex differences included much higher ranking of anxiety dis­
orders in females, and alcohol use disorders and road injuries in males. Between 1990 and 
2017, age-standardized YLD rates for Polish males increased for diabetes (28.6%), drug 
(11.6%) and alcohol (8.6%) use disorders, neonatal disorders (10.7%), depressive disorders 
(5.3%), and low back pain (2.6%). For females, rates increased for diabetes (12.5%), osteoar­
thritis (11.2%), alcohol use disorders (9.7%), schizophrenia (3.6%), and epilepsy (2.9%). In 
terms of all-age YLDs in males, the highest increase was observed for diabetes (79.2%), fol­
lowed by osteoarthritis, urinary diseases, male infertility, stroke, other cardio-vascular diseases, 
and age-related hearing loss (35%-67%). In females, YLDs due to the latter three causes 
increased by 27%-39%, while YLDs due to Alzheimer’s disease increased by 79.9% and those 
due to osteoarthritis by 61.3% in the same period.
Country-level data revealed that in 2017 low back pain ranked first in age-standardized 
YLD rates in CE, followed by falls, headache disorders, and neonatal disorders S1b Fig. The 
pattern has not changed when compared to 1990. The main contributors to age-standardized 
YLDs in CE were comparable to those reported for Poland.
Deviations from expected levels based on SDI. In 2017, all CE countries had OERs for 
all-cause YLDs above or equal to 1 (1.0-1.07), with Albania having the lowest OER and the 
Czech Republic, Hungary, Romania, Bosnia and Herzegovina, and Slovenia tied for the highest 
(Fig 2). Fig 3B shows the OERs for the top 10 causes of YLDs for each country in 2017. All CE 
countries had higher than expected YLDs from falls, with OER greater than 2 for all countries 
but Croatia. YLDs due to iron deficiency were more than triple the expected rate in Romania, 
while Poland and Croatia had higher than expected rates of neonatal sepsis (2.65 and 2.83, 
respectively). The OER for injuries due to other mechanical forces was more than 2 in Monte­
negro (2.14), Slovenia (2.31), and Czech Republic (2.62). OERs for low back pain and age- 
related hearing loss were slightly higher than expected in all CE countries, and the rates for 
stroke were higher than expected in seven countries. Of note, OERs for major depression were 
low in the region (0.59-0.88), with the lowest ratio observed in Albania. YLDs due to anxiety 
disorders, neck pain, and migraine were lower than expected in all CE countries.
Disability-adjusted life years (DALYs)
Overview. Between 1990 and 2017, the age-standardized DALY rate in Poland decreased 
by 31.7%, from 33,741 per 100,000 (95% UI: 30,817-37,080) in 1990 to 23,040 (20,212-26,249) 
in 2017 (Table 1). The rate decreased by 33.4% in males and 29.8% in females (Fig 1). The all­
age DALY rates fell by 8.2% in the same period S1a Table. In the CE region as a whole, the age- 
standardized DALY rate decreased by 30.2%, 31.5% in males and 28.7% in females (Fig 1). CE 
countries with the lowest rates in 1990 were Montenegro, Slovenia, and Bosnia and
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Hercegovina, whereas in 2017, the lowest rates were in Slovenia, the Czech Republic, and Cro­
atia. Poland improved significantly in DALY ranking, from ninth to fifth best, a greater 
improvement than any other CE country except the Czech Republic (from seventh to second) 
and Slovakia (from 10th to sixth). The rise in ranking for Poland was especially strong for the 
group 70 years of age and older (sixth to second), as shown in Fig 4. However, the DALY rate 
decreased the most (68.2%) in the group < 5  years of age. In all other age groups, DALY rates 
decreased by 22%-29%.
In WE, meanwhile, the age-standardized DALY rate decreased by 25.3%, from 24,828 
(22,169-28,000) to 18,536 (15,928-21,551), 30.6% in males and 20.0% in females. In EE the 
rate was higher, at 36,827 (33,891-40,128) in 1990, and dropped to 32,411 (29,593-35,640) in 
2017, i.e., 12.0% overall, 11.5% in males and 13.7% in females (Fig 1).
Main causes o f DALYs. CMNN causes contributed 4.8% (4.3-5.4) to total all-age DALYs 
in Poland in 2017, NCDs contributed 82.4% (81.3-83.5), and injuries 12.7% (11.8-13.9)
(Table 2). All-age DALY rates for CMNN causes fell by 48.2%, from 3,044.8 per 100,000 in 
1990 to 1,577.4 in 2017, whereas those from NCDs fell by 17.8%, from 27,527.7 to 26,980.0, 
and those from injuries by 2.0%, from 5,088.6 to 4.184.2. In CE, CMNN causes contributed 
4.8% (4.4-5.2) to total DALYs, NCDs 83.9% (82.7-84.9), and injuries 11.3% (10.4-12.4). All­
age DALY rates for CMNN causes decreased by 51.6%, from 3,461.8 in 1990 to 1,674.1 in 
2017, whereas those from NCDs increased by 2.1%, from 28,576.8 to 29,185.8, and those from 
injuries decreased by 22.7%, from 5,108.3 to 3,948.4. DALY rates for Level 2 causes are pro­
vided in S2 Table.
As shown in Table 3, among the top 25 Level 3 causes, all-age DALY rates increased for 18; 
the greatest increases were observed for chronic liver diseases (75.0%) and Alzheimer’s disease 
(70.7%). Significant increases were also observed for colorectal cancer (42.0%) and alcohol use 
disorders (41.4%). The difference between changes in all-age and age-standardized rates 
between 1990 and 2017 was 30% or greater for all abovementioned causes except alcohol use 
disorders.
In 2017, the top three causes of age-standardized DALY rates in Poland were IHD, low 
back pain, and falls, even though the rates for IHD and falls declined (62.2% and 13.0%, 
respectively) (Table 3). Stroke, neonatal disorders, lung cancer, headache disorders, road inju­
ries, diabetes, and self-harm were the other top 10 causes of DALYs. Except low back pain, 
headache disorders, and self-harm, for which very slight (0.02%-1.3%) increases were 
observed, all these conditions showed a reduction in age-standardized DALY rates (5.0%- 
62.2%). Stroke, neonatal disorders, and road injuries declined (i.e., improved) in ranking, 
while the remaining top 10 causes (except IHD) increased (Table 3). Among other conditions, 
large reductions in age-standardized DALY rates (36%-58%) were noted for congenital 
defects, COPD, and lower respiratory infections. Alcohol use disorders increased substantially 
in ranking (from 17th to 12th) as did chronic liver diseases (from 23rd to 14th), with an 
increase in age-standardized rates of 20.2% and 36.2%, respectively. By contrast, colorectal 
cancer, age-related hearing loss, and blindness and vision impairment increased in ranks, even 
though their age-standardized rates declined (2.9%-10.1%). There were also increases in ranks 
with slight decreases in rates (0.01%-0.9%) for a small number of other causes, notably anxiety 
and depressive disorders. In general, between 1990 and 2017, of the top 25 causes of age-stan­
dardized DALY rates, declines were observed for all but six; in three of those the increase did 
not exceed 1%.
As Table 3 and S1a Fig show, there was a significant overlap between the top 25 causes of 
DALYs in Poland and the CE region in 2017. Of note, the top nine causes of DALYs in Poland 
and CE were the same, albeit in a slightly different order. However, alcohol use disorders 
ranked 12th in Poland and 19th in the region.
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Fig 4. Ranking o f Central European countries according to all-cause DALY rates for both sexes combined in 1990 and 2017, by age categories.
https://doi.ora/10.1371/iournal.pone.0226766.a004
Table 4 displays country rankings, organized from best (lowest) to worst, according to age- 
standardized DALY rates for the top 25 causes in Poland and other CE countries, for both 
sexes combined, in 1990 and 2017. In 2017, Poland ranked first for depressive disorders, third 
for IHD and stroke, fourth for low back pain and other cardiovascular disorders, fifth for dia­
betes, and sixth for COPD and Alzheimer’s disease. On the other hand, Poland ranked 13th 
(worst) for self-harm, alcohol use disorders, and upper digestive system diseases, and 12th for 
road injuries, headache disorders, and anxiety disorders. Between 1990 and 2017, Poland’s 
ranking among 13 CE countries improved for 11 of the top-25 causes of DALYs and worsened 
for 10.
Deviations from expected levels based on SDI. As shown in Fig 2, the OERs for DALYs 
in the CE countries were generally around or below 1; Albania had the lowest OER (0.77), 
whereas the OER for Poland was 1.0. In four countries, Hungary, Slovakia, Bulgaria, and 
Romania, observed DALY rates were slightly worse than expected (1.01-1.07). Fig 3C shows
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Table 4. Ranking of CE countries according to age-standardized DALY rates, for both sexes combined, in 1990 and 2017.
C ause C ountry
Albania Bosnia Bulgaria C roatia Czech
Repub.
Hungary M acedonia M ontenegro Poland Rom ania Serbia Slovakia Slovenia
Year 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2017 1990 2016
Ischemic heart disease 2 6 6 7 10 13 5 2 12 4 9 9 4 5 3 8 11 3 8 10 7 12 13 11 1 1
Low back pain 11 10 1 1 3 3 6 9 9 6 13 12 2 2 5 5 4 4 10 7 2 8 12 13 8 11
Stroke 4 7 5 8 11 10 6 6 7 2 8 5 13 12 10 13 2 3 9 9 12 11 3 4 1 1
Falls 4 2 5 3 7 7 6 1 n 12 13 9 1 5 3 4 8 10 12 8 2 6 10 11 9 13
Lower respirator)^ infect. 13 12 1 3 11 11 2 1 4 8 5 2 10 6 6 5 7 9 12 13 8 7 9 10 3 4
Road injuries 4 9 1 2 6 11 8 10 5 7 10 1 2 4 3 8 12 12 9 13 7 3 11 5 13 6
Lung cancer 1 1 5 9 3 5 7 6 12 3 13 13 2 8 9 12 11 10 4 7 10 11 8 2 6 4
Neonatal disorders 9 12 11 10 2 8 5 6 3 1 7 4 13 13 10 5 8 7 4 9 12 11 6 3 1 2
Age-related hearing loss 13 13 12 12 8 8 4 5 2 2 3 4 11 11 6 9 9 7 7 6 10 10 5 3 1 1
Congenital birth defects 3 13 2 11 9 12 4 5 5 2 8 6 11 8 1 1 10 7 12 10 13 4 7 I 9 6 3
Headache disorders 1 13 3 4 9 8 13 10 8 2 7 11 6 3 12 9 10 12 2 5 4 6 11 7 5 1
Chronic liver diseases 3 2 7 5 6 10 9 7 8 6 13 11 2 1 3 i i 4 9 10 13 5 4 11 1 12 12 8
Self-harm 2 2 3 9 6 4 10 6 9 8 13 11 i i 5 7 7 13 4 3 11 10 8 5 12 12
COPD 7 3 11 10 6 11 3 7 4 8 12 13 8 5 1 1 10 6 13 9 9 12 2 4 5 2
Diabetes 1 1 8 13 6 6 9 8 7 9 10 7 11 12 12 10 5 5 2 2 13 11 4 4 3 3
Other cardiovascular 7 12 12 11 13 13 10 1 8 10 4 3 6 7 1 5 9 4 5 6 3 8 11 9 2 2
Colorectal cancer 1 1 5 7 6 8 8 10 13 6 12 13 2 3 3 2 9 9 4 5 10 11 11 12 7 4
Depressive disorders 1 2 7 3 8 7 11 12 10 10 12 11 4 4 6 8 2 1 3 6 9 9 5 5 13 13
Cardiomyopathy 8 6 5 H i i 2 4 3 2 1 11 10 6 8 10 12 9 11 12 13 7 9 3 4 13 5
Stomach cancer 4 12 3 10 8 9 13 7 6 1 10 5 12 13 1 2 9 8 5 11 2 6 7 4 11 3
Alcohol use disorders 1 1 12 10 5 3 9 7 4 8 13 9 2 2 3 4 11 13 10 5 6 6 8 11 7 12
Alzheimer’s  disease 1 7 2 12 11 10 12 8 9 4 4 3 3 2 10 11 13 6 7 9 5 13 8 5 6 1
Anxiety disorders 2 7 5 5 13 13 12 9 7 3 6 11 3 4 8 8 9 12 i 1 4 6 11 10 10 2
Upper digestive system diseases 8 5 10 6 5 9 1 1 4 4 11 10 3 3 2 7 12 13 13 12 7 8 9 11 6 2
Neck pain 6 13 11 2 8 12 12 11 4 3 2 7 9 4 13 10 10 9 1 8 7 6 5 5 3 1
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Poland is shaded and shown in bold. Colors indicate changes in ranks: red = increase, green = decrease, and white = no change
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the top 10 causes of DALYs in CE and the variation from expected values based on SDI. 
Observed DALYs for IHD were higher than expected in six countries: Bulgaria, Slovakia, Hun­
gary, Romania, the Czech Republic, and Montenegro. For low back pain and falls, observed 
DALYs were greater than expected in all CE countries, with the highest OERs observed for low 
back pain in Albania (1.35) and for falls in Slovenia (2.33). For the remaining causes, strong 
country-specific patterns were observed. The OER for ischemic stroke in CE was 1.57, with the 
highest observed OER in Serbia (2.51) and the lowest in Slovenia (0.82). Particularly high 
OERs were observed for hypertensive heart disease in Bulgaria (5.15) and for intracerebral 
hemorrhage in Montenegro (4.29).
Discussion
Overview of the results
Among the CE countries, the lowest age-standardized DALY and YLL rates in 2017 were 
achieved by Slovenia, followed by the Czech Republic, whereas the highest rates were seen in 
Romania and Bulgaria. Age-standardized DALY and YLL rates in the CE region were substan­
tially higher than the rates in the WE region throughout the study period. However, the differ­
ence was smaller for females compared with males and was diminishing over time, especially 
for females. In fact, the DALY and YLL rates for females in the top-performing CE country in 
2017 were lower than the corresponding WE rates. Furthermore, the age-standardized YLD 
rates for females in the CE region were lower than the corresponding rates in the WE region. 
DALY rates for the CE countries correlated moderately with SDI values; however, some coun­
tries performed much better than expected (e.g., Albania, Slovenia, Macedonia) while others 
performed worse than expected (e.g., Serbia, Bulgaria, Romania, Slovakia). The reasons for 
this variation are probably complex and may involve economic, cultural, historical, and geo­
graphical factors as well as differences in health systems and policies.
Between 1990 and 2017, age-standardized YLL rates for all causes declined in Poland by 
46.0%, whereas YLDs declined by 4.0%, and DALYs by 31.7%. These trends were largely con­
sistent with CE trends for all three metrics. However, Poland performed better than CE in gen­
eral; only three out of 12 CE countries achieved a greater reduction in age-standardized YLL 
rates, and two countries achieved a greater reduction in YLD rates. Poland ranked fifth best 
for DALYs and, along with Slovakia, experienced greater improvements in ranking than any 
other CE country except the Czech Republic.
The top three causes of premature deaths in Poland in 2017 were IHD, lung cancer, and 
stroke, whereas the leading causes of disability were lower back pain, falls, and headache disor­
ders. Of the top 25 causes of premature mortality, only eight appeared in the top 25 causes of 
disability. IHD, lower back pain, and falls were the top-ranking causes of DALYs. Two causes, 
diabetes and self-harm, appeared among the 10 leading causes of DALYs in 2017, though not 
in 1990. Of the 25 most important causes of YLLs and DALYs, IHD, neonatal disorders, and 
congenital defects showed the largest decrease in age-standardized rates from 1990 to 2017, 
followed by road injuries and stroke, while alarming increases for alcohol use disorders and 
chronic liver diseases were observed for both metrics.
Of the top 25 causes of YLLs and YLDs in Poland in 2017, all but three were among the top 
25 in CE in the same year. The ratio of DALYs from NCDs to those from CMNN diseases was 
17.1 in 2017, compared with 9.0 in 1990, showing a strong epidemiological transition. Poland 
had a ratio of observed to expected YLL, YLD, and DALY rates of about 1.0 in 2017; the worst 
performance relative to SDI-based expectations was noted for alcohol use disorders for YLLs, 
neonatal sepsis and falls for YLDs, and alcohol use disorders and falls for DALYs [25].
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Interpretation of trends for major conditions
Age-standardized YLL rates from IHD and stroke have been declining in high-income coun­
tries for several decades, [10] and Poland followed this trend over the past 25 years. Factors 
that may have contributed to the massive declines in death rates from cardiovascular and cere­
brovascular diseases [25] include changes in risk factors, including dietary habits, better blood 
pressure control, improved quality of health services, and adequate access to modern treat­
ment methods, especially pre-hospital emergency care and cardiac surgery (e.g., the POL- 
CARD 2013-2016 program) [26- 29]. However, some high-income countries, notably the US, 
have recently experienced a flattening and possibly a reversal of this long-term trend [24]. This 
may be associated with the epidemic of obesity and sedentary lifestyle as well as other factors. 
To avoid similar developments in Poland, it is paramount that public health efforts to further 
reduce the risk factors for cardiovascular diseases continue and receive strong government 
support [30].
Low back pain is the second most important cause of DALYs in Poland and one of the lead­
ing causes of disability in all CE countries. The economic impact of this condition, due to 
reduced productivity, is also enormous [31]. Close to 40% of low back pain can be attributed 
to known risk factors, such as occupational risks or increased body mass index [11]. While 
insufficient knowledge of risk factors hinders implementation of preventive strategies for this 
condition, ergonomic measures, obesity reduction, physical therapy, analgesic medication, 
and in some cases surgery can be effective in reducing pain and improving function [32].
The age-standardized rate for falls has declined slightly, but the all-age DALYs increased 
due to population aging; rates were greater than expected in Poland, as well as in all other CE 
countries. Multimodal falls prevention programs which target a combination of risk factors, 
including prevention of and screening for osteoporosis, sarcopenia and frailty, and are tailored 
toward selected high-risk groups, should be implemented or expanded to reduce fall-related 
injuries [33- 35]. Such programs, carried out by the European Innovation Partnership on 
Active and Healthy Ageing (EIP AHA), are good examples to learn from [34].
Between 1995 and 2015, infant mortality among preterm births decreased more than three­
fold (128.5 to 36.8 per 1,000 preterm live births), whereas early neonatal mortality decreased 
almost four-fold [36]. This shows how programs focused on CMNN, such as universal access 
to antenatal care for early detection of complications of pregnancy, scrupulous newborn 
screening for congenital birth defects, and adequate neonatal vaccination policies, accompa­
nied by parental education [3, 36] could potentially engender dramatic reductions in DALYs, 
especially in the under-5 age group. However, neonatal disorders are still the fifth leading 
cause of DALYs in Poland, partly because the decrease in infant and neonatal mortality among 
preterm births resulted in longer-lasting disability [36].
Cancer generally causes relatively few YLDs (except in terminal stages) but is a very impor­
tant cause of YLLs. The most DALYs due to cancer in Poland are caused by cancer of the lung 
(ranked sixth overall), followed by colon/rectum, breast, stomach, pancreas, and brain. 
Although age-standardized rates for all major cancers have declined, all-age rates for most can­
cers (e.g., lung, colorectal, breast, pancreas, prostate, brain) are increasing due to population 
aging. Therefore, continued efforts to reduce cancer burden are needed and should include a 
combination of primary prevention focused on established risk factors (smoking, diet, alcohol, 
obesity, physical activity, occupational risks, and other factors), screening, and access to mod­
ern medical, surgical, and radiation treatment [37].
Prevention and treatment of headaches, specifically migraine, remains a challenge, and 
more research into risk factors and underlying biological mechanisms is warranted. Migraine 
should receive special attention not only because of the high burden due to its prevalence and
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associated disability, but also due to a potential association with increased risks of myocardial 
infarction, stroke, venous thromboembolism, and atrial fibrillation or flutter [38].
DALYs due to road injuries have decreased considerably, likely due to better vehicle safety, 
more rigorous regulations and law enforcement, and improvements in the road network, par­
ticularly in the number of motorways [39]. However, Poland ranked second worst in CE in 
terms of DALY rates from road injuries and has the highest number of deaths per billion vehi- 
cle-km [40]. Consequently, intervention priorities, such as pedestrian protection and speed 
management, were defined in the Polish National Program for Road Safety for 2018-2019. 
Hungary, Slovakia, and Slovenia, the recent recipients of the European Transport Safety Coun­
cil road safety awards, are examples to follow in terms of road safety improvements in the CE 
region [41]. Potentially effective measures include mandatory road safety impact assessment of 
road infrastructure projects, road safety audit by an independent team, vehicle owner liability 
for drunk driving and speeding, and higher penalty points and fines, with regulations enabling 
more effective enforcement.
Diabetes (mostly type 2) contributes substantially to both YLLs and YLDs and although the 
age-adjusted DALY rate has declined somewhat compared to 1990, a slightly increasing trend 
was noted in the last decade [42]. Due to its strong relationship with obesity and sedentary life­
style, prevalence of type 2 diabetes is unlikely to decrease in the foreseeable future. At the pop­
ulation level, it is well documented that implementation of early screening strategies for 
identification of individuals at risk (including those with prediabetes) may significantly reduce 
the prevalence of diabetes, overall costs of treatment of conditions associated with hyperglyce­
mia, and premature deaths [42, 43]. Early detection and treatment of diabetes in Poland and 
other CE countries could be facilitated by improvements in diabetes surveillance systems, 
including the development of diabetes registries [42].
Poland is ranked worst in CE in terms of DALY rates from self-harm and experienced a sig­
nificant worsening in ranking since 1990. Furthermore, suicide rates remained fairly constant 
since 1990, whereas CE as a whole has seen a gradual improvement. Therefore, measures that 
reduce the incidence of suicide, listed in the Polish National Program for the Preservation of 
Mental Health for 2017-2022, e.g., prevention, early detection, and treatment of depression, 
creation of suicide prevention centers, or enhanced training in suicide prevention for profes­
sionals and community volunteers, should be integrated with the existing methods of assessing 
and managing suicide risk [44]. It should be noted that depressive and anxiety disorders are 
important contributors to DALYs regardless of their potential link with self-harm. Although 
the burden of depression is currently smaller in Poland than in other CE countries, it is likely 
to increase if Poland follows the trend observed in WE and other high-income countries [45]. 
Therefore, current efforts to reduce stigma of mental illness, improve access to professional 
treatment and, most importantly, further embed a range of preventive strategies oriented 
toward high-risk groups in primary care [3, 44, 45] should be expanded.
For alcohol use disorders, the current DALY rate in Poland is much higher than in any 
other CE country and higher than in WE as a whole (albeit lower than in EE countries) [10].
In addition, YLLs for this cause are three times higher than expected. An increase in DALY 
rates occurred mainly in the period 2000-2007; a slight decline was observed in the last decade. 
Of note, alcohol consumption in Poland (similar to some Northern and Eastern European 
countries) differs from the Western European pattern, as Poles tend to drink hard liquor (e.g., 
vodka) and beer, rather than wine, and tend to engage in binge drinking more frequently [3, 
46]. The large burden of alcohol use disorders urgently requires a policy response (e.g., taxa­
tion and restrictions on availability and marketing) and a health system response (expansion 
of treatment) [47, 48].
PLOSONE | https://doi.org/10.1371/iournal.pone.0226766 March 2, 2020 21 /29
©PLO SIO N E Changes in disease burden in Poland between 1990-2017 in comparison with other Central European countries
Alzheimer’s disease and osteoarthritis are ranked outside of the top 10 causes of DALYs 
and represent different categories of diseases, but have some common features. They are very 
common, strongly related to age, can be severely disabling, and are difficult to prevent or treat 
effectively, although loss of weight can help prevent osteoarthritis and joint replacement is 
effective for advanced disease. These two conditions are important because they are responsi­
ble for a significant proportion of DALYs and are unlikely to diminish in the foreseeable 
future.
Over the past 27 years in Poland, the conditions that demonstrated the largest drop in 
DALY rates and ranking are lower respiratory infections and COPD. For COPD, the most 
important risk factor is smoking, and a reduction in COPD is mostly a result of long-term 
decreasing trends in smoking rates. A similar trend has been observed elsewhere [49].
Socioeconomic changes and epidemiological transition
Factors that might have affected the study findings are likely complex. Although it is difficult 
to identify the specific causes of the differences in YLLs, YLDs and DALYs among the CE 
countries, differences in political systems, socioeconomic conditions, health behaviors (e.g., 
smoking, alcohol, diet), and health care systems are likely to play a role [50]. Changes in popu­
lation health have paralleled rapid socio economic development that took place in these coun­
tries over the past quarter of a century and can be, at least partly, attributed to it [7, 8, 51, 52]. 
SDI in Poland improved from 0.66 in 1990 to 0.84 in 2017, compared with increases from 0.66 
to 0.81 in the CE region, 0.68 to 0.79 in EE, and 0.76 to 0.86 in WE. Poland ranked third for 
SDI in CE in 2017 and second (after Bosnia and Herzegovina) for relative improvement in 
SDI between 1990 and 2017.
There have been substantial between-country differences in CE in terms of national income 
and health expenditures (HE) [53]. In Poland, HE per capita increased from US$ 197 in 1995 
to 809 in 2016 [54]. As a result, Poland improved its position from 6th to 4th during this period. 
Greater relative improvements were seen in Bosnia and Herzegovina (US$ 44.6 to 444) and 
Romania (US$ 53 to 476) [2, 55]. However, as a percentage of the GDP, HE in Poland in 2016 
ranked third lowest among the CE countries [5]. Plans to increase the health budget in the 
next decade have been announced [56]. Nonetheless, improvements in health care and public 
health programs, in addition to changes in the distribution of risk factors, likely have played an 
important role in reducing disease burden. In particular, a dramatic drop in neonatal and 
infant deaths can be partly explained by substantial improvements in prenatal and postpartum 
care over the past two decades [57].
Detailed analyses of changes in DALY rates in Poland and other CE countries provide 
insights into public health successes and areas where some countries might be falling behind. 
This, in turn, could help galvanize efforts aimed at minimizing the gap in disease burden 
between CE and WE. One-third of the decline in age-standardized DALYs in Poland between 
1990 and 2017 was due to CMNN causes. All-age DALY rates for CMNN causes decreased by 
half, whereas injuries and especially NCDs decreased to a lesser extent. A similar trend was 
seen in other CE countries. In Poland and CE as a whole, NCDs are now responsible for much 
more health loss due to premature death or disability than injuries and CMNN diseases. The 
continuous increase in the contribution of NCDs to total disease burden in Poland and CE 
mimics the epidemiological transition taking place globally [12, 58, 59]. However, differences 
between locations were observed for the ratios of DALYs from NCDs to those from CMNN 
diseases in 1990 and 2017. The rising problem of NCDs poses challenges for the Polish health 
system that need to be addressed. Recently implemented national programs for cancer, cardio­
vascular diseases, mental health, as well as the promotion of healthy and active aging [25, 34,
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60- 63] and the Health Needs Map project for 30 groups of diseases [64] are positive develop­
ments in this area.
The shift from acute diseases to chronic disability is associated with the need for qualified 
health personnel. However, since joining the European Union, Poland has faced a dramatic 
shortage of physicians (mainly specialists) and nurses, who often seek jobs in other EU coun­
tries, as well as ongoing workforce aging [65]. These are important obstacles to strengthening 
the health care system. The Polish government has already identified training of health profes­
sionals as a top priority, but their retention needs system changes which are challenging to 
implement.
Health inequalities
Poland (and CE in general) is characterized by a large difference in age-standardized YLLs and 
DALYs between males and females, with males experiencing much higher YLL rates for all 
leading causes of death. The male to female ratio for DALYs in Poland decreased only slightly, 
from 1.6 in 1990 to 1.5 in 2017, compared to a drop from 1.3 to 1.2 in WE. Also, greater rela­
tive declines in YLLs and YLDs were observed for females than males during this period. In 
terms of non-fatal health outcomes, all-cause YLD rates in males and females are similar, 
although there are large differences for some conditions. Differences in premature mortality 
between males and females can be partially explained by differences in the distribution of risk 
factors (e.g., smoking, alcohol, diet, a lack of physical activity and occupational exposures) for 
major categories of chronic conditions, such as CVD and cancer [66, 67]. In addition, men are 
less likely to participate in screening programs [67]. Other factors, including biopsychological 
differences, may also be important, especially for mental health and self-harm [7]. The YLL 
rate for self-harm in Poland is almost eightfold higher in males. The male/female mortality gap 
is a serious concern that, in our view, has not received sufficient attention, and few policies 
explicitly designed to reduce this gap have been implemented. There also exist substantial dis­
parities in health between the provinces, rural versus urban areas, and socioeconomic groups 
within Poland and other CE countries [3], but such data are currently not available from the 
GBD.
Limitations
Some important limitations of this study should be recognized. First of all, our results share 
the limitations of GBD data in general, as described in detail in GBD publications [9- 12, 14,
15, 58, 59]. They include variation across locations in cause of death certification and report­
ing, insufficient data on disease prevalence and severity distribution, methodological issues 
around disease definitions, modeling of comorbidity, and accuracy of disability weights 
assigned to different diseases. Second, although the quality of data in Poland has improved 
compared with 1990 [3, 10], the existing information systems have important gaps that limit 
their ability to monitor population health and potential health threats. According to the Polish 
Office of Health Statistics (GUS), the proportion of ill-defined causes of deaths in Poland is 
very high and on the rise throughout the last decade [68]. In 2016, of the total of 388,009 
deaths, causes assigned for 113,322 (29.2%) were considered “garbage codes” (codes that 
should not be used for the underlying cause of death) by the GBD. These garbage codes influ­
ence the quality of information on the causes of death, which may hinder the identification of 
health priorities and planning of health interventions [69]. Improving the quality of cause of 
death certification is possible through training of physicians, regulatory measures, and techno­
logical innovation. A good example of the latter is a recent effort to introduce electronic death 
certification, combined with online support and automated verification of the code [70]. In
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our view, this issue should be considered an urgent priority by the health care administrators 
in every country where the “garbage code” problem is substantial. Third, there is a lack of ade­
quate information regarding data generated by primary and specialist care which are related to 
less dramatic health events than hospitalization or death [3]. A pilot program to address this 
data gap, involving 100 primary care units, has been recently introduced [71]. Fourth, in 
assessing factors that may have influenced changes in disease burden we have not been able to 
take into account migration, both within Europe and between CE and countries on other con­
tinents. For Poland and most CE countries, the number of immigrants from the Middle East 
and North Africa has been relatively low. However, over the past two decades Poland has expe­
rienced high levels of immigration (primarily from Ukraine) and emigration (primarily to the 
UK, Germany and other EU countries). Similar—although lower-migration into and out of 
the country was observed between 2000 and 2011 in Romania [72]. Finally, current data do 
not consider variation in health indicators across regions (provinces) within each CE country. 
To address this limitation, Poland has recently initiated a collaboration with the GBD to gener­
ate subnational estimates of disease burden.
Conclusions
Health in Poland is improving, and the country outperforms CE as a whole for YLLs, YLDs, 
and DALYs. This is a result of a faster decrease in age-standardized YLL rates between 1990 
and 2017 compared with CE, accompanied by faster, however more modest, declines in YLDs. 
As a result, the all-cause age-standardized DALY rate decreased by about a third. Poland has 
made notable improvements in preventing child deaths, cardiovascular diseases, and road 
injuries. On the other hand, there are worrisome trends in alcohol use disorders, chronic liver 
disease, diabetes, and self-harm. The shift to chronic disability, together with marked between- 
gender health inequalities, poses a challenge for the healthcare system, particularly in light of a 
significant shortage and aging of the workforce and relatively low public health expenditures.
Geographical variation in leading causes of premature death and disability in CE is fairly 
limited, although some between-country differences exist. Health policies and practices in 
good regional performers offer examples that can be followed by other countries in order to 
reduce disease burden. To minimize the gap between CE and WE, an integrated response, 
which addresses the causes of death and ill-health, particularly those for which rates have 
increased and higher-than-expected rates are observed, is needed in all CE countries.
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